Phio Pharmaceuticals Corp. SEC filings PHIO
Phio Pharmaceuticals Corp. has 894 filings in SEC EDGAR's recent list, going back to Oct 25, 2011. Its latest annual report, Form ARS, was filed on Aug 14, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Aug 14, 2026 | — |
| DEF 14A | Proxy statement | Aug 14, 2026 | Sep 28, 2026 |
| DEFA14A | Additional proxy material | Aug 28, 2025 | — |
| DEFA14A | Additional proxy material | Jul 30, 2025 | — |
| DEF 14A | Proxy statement | Jul 30, 2025 | Sep 11, 2025 |
| DEFA14A | Additional proxy material | May 8, 2024 | — |
| DEF 14A | Proxy statement | May 8, 2024 | Jun 17, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 22, 2024 | Jun 17, 2024 |
| DEFA14A | Additional proxy material | Jun 9, 2023 | — |
| DEF 14A | Proxy statement | Jun 9, 2023 | Jul 20, 2023 |
| DEFA14A | Additional proxy material | Dec 2, 2022 | — |
| DEF 14A | Proxy statement | Nov 30, 2022 | Jan 4, 2023 |
| PRE 14A | Preliminary proxy statement | Nov 16, 2022 | Jan 4, 2023 |
| DEFA14A | Additional proxy material | Jun 30, 2022 | — |
| DEF 14A | Proxy statement | Jun 30, 2022 | Aug 9, 2022 |
| DEFA14A | Additional proxy material | May 6, 2021 | — |
| DEF 14A | Proxy statement | Apr 30, 2021 | Jun 15, 2021 |
| DEFA14A | Additional proxy material | Aug 28, 2020 | — |
| DEF 14A | Proxy statement | Aug 28, 2020 | Oct 8, 2020 |
| DEFA14A | Additional proxy material | Dec 13, 2019 | — |
| DEFA14A | Additional proxy material | Dec 13, 2019 | — |
| DEF 14A | Proxy statement | Nov 22, 2019 | Dec 12, 2019 |
| PRE 14A | Preliminary proxy statement | Nov 8, 2019 | Dec 31, 2019 |
| DEFA14A | Additional proxy material | Oct 25, 2019 | — |
| DEFA14A | Additional proxy material | Oct 15, 2019 | — |
| DEFA14A | Additional proxy material | Oct 11, 2019 | — |
| DEFA14A | Additional proxy material | Aug 30, 2019 | — |
| DEF 14A | Proxy statement | Aug 30, 2019 | Aug 22, 2019 |
| PRE 14A | Preliminary proxy statement | Aug 12, 2019 | Oct 10, 2019 |
| DEFA14A | Additional proxy material | Apr 26, 2018 | — |
| DEF 14A | Proxy statement | Apr 26, 2018 | Jun 5, 2018 |
| PRE 14A | Preliminary proxy statement | Apr 13, 2018 | Jun 5, 2018 |
| DEFA14A | Additional proxy material | Apr 27, 2017 | — |
| DEF 14A | Proxy statement | Apr 27, 2017 | Jun 6, 2017 |
| PRE 14A | Preliminary proxy statement | Apr 12, 2017 | Jun 6, 2017 |
| DEFA14A | Additional proxy material | Nov 4, 2016 | — |
| DEF 14A | Proxy statement | Nov 4, 2016 | Dec 15, 2016 |
| DEF 14A | Proxy statement | Mar 7, 2016 | Apr 14, 2016 |
| PRE 14A | Preliminary proxy statement | Feb 24, 2016 | Apr 14, 2016 |
| DEFA14A | Additional proxy material | Apr 16, 2015 | — |
| DEF 14A | Proxy statement | Apr 16, 2015 | Jun 1, 2015 |
| DEFA14A | Additional proxy material | Apr 15, 2014 | — |
| DEF 14A | Proxy statement | Apr 15, 2014 | Jun 2, 2014 |
| PRE 14A | Preliminary proxy statement | Apr 4, 2014 | Jun 2, 2014 |
| DEFA14A | Additional proxy material | Apr 26, 2013 | — |
| DEF 14A | Proxy statement | Apr 26, 2013 | Jun 7, 2013 |
Showing 46 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PHIO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- King Of Prussia, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1533040
- Former names
- RXi Pharmaceuticals Corp (until Nov 14, 2018)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.